TY - JOUR
T1 - Human IFN- immunity to mycobacteria is governed by both IL-12 and IL-23
AU - Martínez-Barricarte, Rubén
AU - Markle, Janet G.
AU - Ma, Cindy S.
AU - Deenick, Elissa K.
AU - Ramírez-Alejo, Noé
AU - Mele, Federico
AU - Latorre, Daniela
AU - Mahdaviani, Seyed Alireza
AU - Aytekin, Caner
AU - Mansouri, Davood
AU - Bryant, Vanessa L.
AU - Jabot-Hanin, Fabienne
AU - Deswarte, Caroline
AU - Nieto-Patlán, Alejandro
AU - Surace, Laura
AU - Kerner, Gaspard
AU - Itan, Yuval
AU - Jovic, Sandra
AU - Avery, Danielle T.
AU - Wong, Natalie
AU - Rao, Geetha
AU - Patin, Etienne
AU - Okada, Satoshi
AU - Bigio, Benedetta
AU - Boisson, Bertrand
AU - Rapaport, Franck
AU - Seeleuthner, Yoann
AU - Schmidt, Monika
AU - Ikinciogullari, Aydan
AU - Dogu, Figen
AU - Tanir, Gonul
AU - Tabarsi, Payam
AU - Bloursaz, Mohammed Reza
AU - Joseph, Julia K.
AU - Heer, Avneet
AU - Kong, Xiao Fei
AU - Migaud, Mélanie
AU - Lazarov, Tomi
AU - Geissmann, Frédéric
AU - Fleckenstein, Bernhard
AU - Arlehamn, Cecilia Lindestam
AU - Sette, Alessandro
AU - Puel, Anne
AU - Emile, Jean François
AU - van de Vosse, Esther
AU - Quintana-Murci, Lluis
AU - Di Santo, James P.
AU - Abel, Laurent
AU - Boisson-Dupuis, Stéphanie
AU - Bustamante, Jacinta
AU - Tangye, Stuart G.
AU - Sallusto, Federica
AU - Casanova, Jean Laurent
N1 - Funding Information:
The Laboratory of Human Genetics of Infectious Diseases was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) grant numbers 5R37AI095983, R01AI089970, and K99AI127932; the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the NIH grant number UL1TR001866; the Rockefeller University; the St. Giles Foundation; the European Research Council (ERC-2010-AdG-268777 and grant no. 323183); Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Descartes University; the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); and the French National Research Agency (ANR) under the “Investissement d’avenir” program (grant ANR-10-IAHU-01), ANR-TBPATHGEN (grant ANR-14-CE14-0007-01), ANR-IFNPHOX (grant ANR13-ISV3-0001-01), and ANR-GENMSMD (grant ANR16-CE17-0005-01). This work was supported by NIAID award no. U19AI118626 (to A.S. and F.S.). J.G.M. was funded by the Canadian Institutes of Health Research, the NIH Translational Science Award (CTSA) program (no. UL1 TR000043), the Swiss National Science Foundation (grant no. IZKOZ3_173586), the Charles H. Revson Foundation, and the NIAID (1K99AI127932-01A1). R.M.-B. was supported by the European Molecular Biology Organization (EMBO). N.R.-A. was supported by the National Council of Science and Technology of Mexico (CONACYT, 264011) and the Stony Wold-Herbert Fund Fellowship Grant. Y.I. was supported by the AXA Research Fund. S.G.T., E.K.D., and C.S.M. are supported by research grants and fellowships from the National Health and Medical Research Council of Australia (S.G.T., C.S.M., and E.K.D.) and the Office for Health and Medical Research of the State Government of NSW Australia (C.S.M.). A.S. is supported by NIH research grant HHSN272200900044C. J.B. is supported by SRC2017. The Institute for Research in Biomedicine and F.S. are supported by the Helmut Horten Foundation. S.O. was supported by the Aid for Scientific Research Grant from the Japanese Society for the Promotion of Science (16H05355) and the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development.
Publisher Copyright:
Copyright © 2018 The Authors.
PY - 2018
Y1 - 2018
N2 - Hundreds of patients with autosomal recessive, complete IL-12p40 or IL-12R1 deficiency have been diagnosed over the last 20 years. They typically suffer from invasive mycobacteriosis and, occasionally, from mucocutaneous candidiasis. Susceptibility to these infections is thought to be due to impairments of IL-12–dependent IFN- immunity and IL-23–dependent IL-17A/IL-17F immunity, respectively. We report here patients with autosomal recessive, complete IL-12R2 or IL-23R deficiency, lacking responses to IL-12 or IL-23 only, all of whom, unexpectedly, display mycobacteriosis without candidiasis. We show that T, T, B, NK, ILC1, and ILC2 cells from healthy donors preferentially produce IFN- in response to IL-12, whereas NKT cells and MAIT cells preferentially produce IFN- in response to IL-23. We also show that the development of IFN-–producing CD4+ T cells, including, in particular, mycobacterium-specific TH1* cells (CD45RA−CCR6+), is dependent on both IL-12 and IL-23. Last, we show that IL12RB1, IL12RB2, and IL23R have similar frequencies of deleterious variants in the general population. The comparative rarity of symptomatic patients with IL-12R2 or IL-23R deficiency, relative to IL-12R1 deficiency, is, therefore, due to lower clinical penetrance. There are fewer symptomatic IL-23R– and IL-12R2–deficient than IL-12R1–deficient patients, not because these genetic disorders are rarer, but because the isolated absence of IL-12 or IL-23 is, in part, compensated by the other cytokine for the production of IFN-, thereby providing some protection against mycobacteria. These experiments of nature show that human IL-12 and IL-23 are both required for optimal IFN-–dependent immunity to mycobacteria, both individually and much more so cooperatively.
AB - Hundreds of patients with autosomal recessive, complete IL-12p40 or IL-12R1 deficiency have been diagnosed over the last 20 years. They typically suffer from invasive mycobacteriosis and, occasionally, from mucocutaneous candidiasis. Susceptibility to these infections is thought to be due to impairments of IL-12–dependent IFN- immunity and IL-23–dependent IL-17A/IL-17F immunity, respectively. We report here patients with autosomal recessive, complete IL-12R2 or IL-23R deficiency, lacking responses to IL-12 or IL-23 only, all of whom, unexpectedly, display mycobacteriosis without candidiasis. We show that T, T, B, NK, ILC1, and ILC2 cells from healthy donors preferentially produce IFN- in response to IL-12, whereas NKT cells and MAIT cells preferentially produce IFN- in response to IL-23. We also show that the development of IFN-–producing CD4+ T cells, including, in particular, mycobacterium-specific TH1* cells (CD45RA−CCR6+), is dependent on both IL-12 and IL-23. Last, we show that IL12RB1, IL12RB2, and IL23R have similar frequencies of deleterious variants in the general population. The comparative rarity of symptomatic patients with IL-12R2 or IL-23R deficiency, relative to IL-12R1 deficiency, is, therefore, due to lower clinical penetrance. There are fewer symptomatic IL-23R– and IL-12R2–deficient than IL-12R1–deficient patients, not because these genetic disorders are rarer, but because the isolated absence of IL-12 or IL-23 is, in part, compensated by the other cytokine for the production of IFN-, thereby providing some protection against mycobacteria. These experiments of nature show that human IL-12 and IL-23 are both required for optimal IFN-–dependent immunity to mycobacteria, both individually and much more so cooperatively.
UR - http://www.scopus.com/inward/record.url?scp=85057006182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057006182&partnerID=8YFLogxK
U2 - 10.1126/sciimmunol.aau6759
DO - 10.1126/sciimmunol.aau6759
M3 - Article
C2 - 30578351
AN - SCOPUS:85057006182
SN - 2470-9468
VL - 3
JO - Science Immunology
JF - Science Immunology
IS - 30
M1 - eaau6759
ER -